CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ViGenCell Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ViGenCell Inc
66, Gasan-ro 9-gil, Geumcheon-gu
Phone: +82 234781686p:+82 234781686 SEOUL, 08513  South Korea Ticker: 308080308080
Business Summary
ViGenCell Inc is a Korea-based company principally engaged in the development of cell therapy business. The Company is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. It is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Tae GyuKim 65
Vice President, Director Gyeong MukKim 54
Assistant Managing Director Hyeon JeongSon 50
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 80 (As of 12/31/2022)
Outstanding Shares: 19,263,740 (As of 6/30/2024)
Shareholders: 54,117
Stock Exchange: KDQ
Fax Number: +82 25337456


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024